Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia

Published:2022-03-04 Issue:3 Volume:15 Page:183-194
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Wolska-Washer Anna¹²^ORCID,Robak Tadeusz³⁴^ORCID

Affiliation:

1. Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland

2. Department of Hematooncology, Copernicus Memorial Hospital, Lodz, Poland

3. Department of Hematology, Medical University of Lodz, Lodz, Poland

4. Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland

Funder

grants funding from the Medical University of Lodz

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2022.2054800

Reference63 articles.

1. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union

3. Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia

4. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

5. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma;Expert Opinion on Drug Metabolism & Toxicology;2024-03-25

2. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11

3. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors;Blood Advances;2023-09-27

4. Acalabrutinib in chronic lymphocytic leukemia;Expert Opinion on Pharmacotherapy;2023-03-23

5. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages;Expert Opinion on Biological Therapy;2022-11-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3